In this NDTV opinion piece, Bill Gates, co-chair of the Bill & Melinda Gates Foundation, reflects on his recent trip to India, writing, “During my recent visit, I had a chance to see the latest progress on things that matter a lot to us: on eradicating polio and curtailing the spread of infectious diseases like HIV/AIDS and tuberculosis, for example.” He continues, “And I saw how India is emerging as a model and increasingly a catalyst for improvement in other developing countries,” adding, “The current situation in India is quite hopeful.”
The Wall Street Journal reports on a rise of multi-drug resistant tuberculosis (TB) in India, writing, “India’s slow response to years of medical warnings now threatens to turn the country into an incubator for a mutant strain of tuberculosis that is proving resistant to all known treatments, raising alarms of a new global health hazard.” The newspaper continues, “Spread of the strain could return tuberculosis to the fatal plague that killed two-thirds of people afflicted, before modern treatments were developed in the 1940s, said Dr. Mario Raviglione, director of the Stop TB Department of the World Health Organization.” The newspaper notes, “The WHO is now assisting India to combat the strain” (Anand, 6/19).
Several articles published on Tuesday examine tuberculosis (TB) in South Africa. “According to the World Health Organization (WHO), the country has the highest rate of new TB cases annually,” VOA News writes, adding, “Thousands of people in South Africa continue to be infected by a disease that’s been virtually eradicated in the developed world.” The news service discusses TB among children in the country and notes, “The WHO says every year at least 500,000 babies and children become infected with TB worldwide and an estimated 70,000 die of it — many in South Africa, India and China” (Taylor, 6/19).
“The potential for antiretroviral medicine to reduce transmission of HIV and tuberculosis has been demonstrated, but the challenges of using treatment to prevent infection will need to be tackled country by country, and with focus on people for whom it will have the biggest impact, the latest bulletin on HIV treatment from the World Health Organization says,” the Center for Global Health Policy’s “Science Speaks” blog reports. “WHO’s June 2012 Antiretroviral Treatment as Prevention (TasP) of HIV and TB Programmatic Update is the latest of a series of documents the organization says will lead to a completed set of guidelines on treatment and prevention in July 2013,” the blog reports, noting, “The organization also plans to release new recommendations in time for the July International AIDS Conference, addressing the preventative use of antiretroviral medicine by people who are uninfected but potentially exposed to HIV, including those involved in commercial sex work, in ongoing relationships with infected partners, and men who have sex with men” (6/18).
During a live webcast discussing recent changes at the Global Fund to Fight AIDS, Tuberculosis and Malaria, “[p]anelists discussed the fund’s new strategy and what this strategy means for the global fight against these three diseases,” GlobalPost’s “Global Pulse” blog reports. J. Stephen Morrison, senior vice president and director of the Global Health Policy Center at the Center for Strategic and International Studies, noted the Global Fund’s new general manager, Gabriel Jaramillo, had moved quickly in focusing on restructuring and realigning the fund, according to the blog. Todd Summers, independent consultant and chair of the Strategy, Investment & Impact Committee at the Global Fund, said, “Now we see lots of opportunity to really make a big difference and change forever the trajectory” of the epidemics, “Global Pulse” notes.
South African TB Conference Hears Demands From Advocacy Organizations To Improve, Decentralize Treatment
The 2012 South African TB Conference opened Tuesday night in Durban, with the Treatment Action Campaign, Section27, and Oxfam delivering “a memorandum containing five demands to conference organizers shortly before the opening,” health-e News Service reports. The organizations “called for patients with drug-resistant TB who were failing to respond to treatment to be given ‘access to the best available medicines,'” even if they are not yet approved by the Medicines Control Council; “the diagnosis of all people living with TB”; and “the decentralization of care for people with drug-resistant TB, enabling them to be treated at home instead of hospitalized for long periods,” the news service writes (Cullinan, 6/13).
In this post in the Global Health Governance blog, Jenilee Guebert, director of research for the global health diplomacy program and G8 research group at the University of Toronto’s Munk School of Global Affairs, writes that, “for the second year in a row, the amount of attention devoted to global health” at the annual G8 summit, which took place at Camp David in Maryland in May, has declined. “Global health was not completely absent from the summit,” she continues, highlighting several health initiatives discussed at the meeting, including the New Alliance for Food Security and Nutrition, launched “to accelerate the flow of private capital to African agriculture” with an aim of “lift[ing] 50 million people out of poverty over the next decade.”
“One in 10 cases of tuberculosis in China cannot be treated by the most commonly-used drugs, driven by a lack of testing and misuse of medicine, according to a national survey that showed for the first time the size of the drug-resistant epidemic,” the Associated Press reports (Wong, 6/7). “‘In 2007, one third of the patients with new cases of tuberculosis and one half of the patients with previously treated tuberculosis had drug-resistant disease,’ said the study in the New England Journal of Medicine,” Agence France-Presse reports, adding, “Even more, the prevalence of multi-drug resistant [tuberculosis (MDR-TB)] in new cases (5.7 percent) was nearly twice the global average, said the study” (6/6).
“Researchers who tested a novel type of antibiotic against multi-drug-resistant tuberculosis [MDR-TB] are reporting that nearly half of patients who got the new drug cleared the bacteria from their lung fluid in two months,” according to a study published Thursday in the New England Journal of Medicine, Reuters reports. Japanese pharmaceutical company Otsuka developed the experimental drug, delamanid, and “also designed and financed the clinical trial, which took place in 17 medical centers across nine countries,” the news service writes (Emery, 6/6).
In a guest post on the Global Health Technologies Coalition’s “Breakthroughs” blog, Jamie Elizabeth Rosen, media and communications manager at Aeras, interviews Steven Reed, founder, president, and chief scientific officer of the Infectious Disease Research Institute (IDRI), “a 120-person non-profit biotech committed to applying innovative science to the research and development of products to prevent, detect, and treat infectious diseases of poverty.” Aeras, “a non-profit biotech focused on developing vaccines against TB,” has partnered with IDRI to develop a novel tuberculosis (TB) vaccine candidate, Rosen notes and summarizes Reed’s responses to questions regarding TB vaccine development (Taylor, 5/29).